Tropical Journal of Pharmaceutical Research

The AJOL site is currently undergoing a major upgrade, and there will temporarily be some restrictions to the available functionality.
-- Users will not be able to register or log in during this period.
-- Full text (PDF) downloads of Open Access journal articles will be available as always.
-- Full text (PDF) downloads of subscription based journal articles will NOT be available
We apologise for any inconvenience caused. Please check back soon, as we will revert to usual policy as soon as possible.

A Qualitative and Quantitative Assay to Study DNA/Drug Interaction Based on Sequence Selective Inhibition of Restriction Endonucleases

SA Hassan, L Chauhan, R Barthwal, A Dixit


Purpose: To explore the use of restriction inhibition assay (RIA) to study the binding specificity of some anticancer drugs.
Methods: A 448 bp DNA fragment derived from pBCKS+ plasmid (harboring the polylinker region with multiple restriction endonuclease sites) was used as a template for sequence selective inhibition of the test drugs. The template was incubated with different concentrations of anticancer drugs (adriamycin, daunomycin, mitoxantrone, distamycin-A, berberine and palmatine) prior to digestion with restriction endonucleases - HindIII, EcoRI and EcoRV.
Results: Mitoxantrone, adriamycin and daunomycin showed specificity for HindIII restriction site (5’- AAGCTT-3’) at 220, 100 and 100 ìM concentration, respectively. Conversely, distamycin-A showed an affinity for EcoRI (5’-AAATGC-3’) restriction sites at a concentration of 10 ìM. No binding was observed for berberine and palmatine at a maximum concentration of 2 mM at HindIII, EcoRI and EcoRV restriction sites, respectively.
Conclusion: The inhibition of endonucleases by mitoxantrone, adriamycin, daunomycin, distamycin-A,provides direct evidence of the co-existence of concentration and sequence specificity for drug-DNA interaction as well as the need to explore the possible use of RIA for demonstrating the binding
specificity of anticancer drugs.

Keywords: Restriction endonucleases, Restriction sites, Anticancer drugs, Restriction inhibition assay (RIA), Binding specificity.
AJOL African Journals Online